Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Daniel L. Suzman, MD

Advertisement

Articles by Daniel L. Suzman, MD

In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? Yes; We Must Beware of Drawing Conclusions From a Subset Analysis

ByDaniel L. Suzman, MD,Emmanuel S. Antonarakis, MD
October 15th 2014

Ultimately, while further follow-up will be enlightening, we believe that there is sufficient evidence now from the primary analysis of CHAARTED to justify the combination of docetaxel and androgen deprivation therapy in all men with metastatic hormone-sensitive prostate cancer.

Advertisement

Latest Updated Articles

  • In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? Yes; We Must Beware of Drawing Conclusions From a Subset Analysis
    In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? Yes; We Must Beware of Drawing Conclusions From a Subset Analysis

    October 15th 2014



Advertisement
Advertisement

Trending on CancerNetwork

1

FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer

2

64Cu-SAR-bisPSMA Earns FDA Breakthrough Designation in Recurrent Prostate Cancer

3

Selecting Patients With High-Risk Prostate Cancer for Perioperative ARPI Therapy

4

Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist

5

FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us